Left Ventricular Hypertrophy: Major Risk Factor in Patients with Hypertension: Update and Practical Clinical Applications

被引:130
作者
Katholi, Richard E. [1 ]
Couri, Daniel M. [1 ]
机构
[1] Prairie Cardiovasc Consultants Ltd, 619 E Mason St,Ste 4P57, Springfield, IL 62701 USA
关键词
D O I
10.4061/2011/495349
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Left ventricular hypertrophy is a maladaptive response to chronic pressure overload and an important risk factor for atrial fibrillation, diastolic heart failure, systolic heart failure, and sudden death in patients with hypertension. Since not all patients with hypertension develop left ventricular hypertrophy, there are clinical findings that should be kept in mind that may alert the physician to the presence of left ventricular hypertrophy so a more definitive evaluation can be performed using an echocardiogram or cardiovascular magnetic resonance. Controlling arterial pressure, sodium restriction, and weight loss independently facilitate the regression of left ventricular hypertrophy. Choice of antihypertensive agents may be important when treating a patient with hypertensive left ventricular hypertrophy. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers followed by calcium channel antagonists most rapidly facilitate the regression of left ventricular hypertrophy. With the regression of left ventricular hypertrophy, diastolic function and coronary flow reserve usually improve, and cardiovascular risk decreases.
引用
收藏
页数:10
相关论文
共 75 条
[1]
Anversa P., 1990, CARDIOVASCULAR REV R, V11, P34
[2]
DOES PHYSICAL-ACTIVITY LOWER BLOOD-PRESSURE - A CRITICAL-REVIEW OF THE CLINICAL-TRIALS [J].
ARROLL, B ;
BEAGLEHOLE, R .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1992, 45 (05) :439-447
[3]
Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension - A randomized controlled trial [J].
Bakris, GL ;
Fonseca, V ;
Katholi, RE ;
McGill, JB ;
Messerli, FH ;
Phillips, RA ;
Raskin, P ;
Wright, JT ;
Oakes, R ;
Lukas, MA ;
Anderson, KM ;
Bell, DSH .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (18) :2227-2236
[4]
Carvedilol prevents severe hypertensive cardiomyopathy and remodeling [J].
Barone, FC ;
Campbell, WG ;
Nelson, AH ;
Feuerstein, GZ .
JOURNAL OF HYPERTENSION, 1998, 16 (06) :871-884
[5]
CARDIAC-ARRHYTHMIAS AND LEFT-VENTRICULAR HYPERTROPHY IN SYSTEMIC HYPERTENSION AND THEIR INFLUENCES ON PROGNOSIS [J].
BAYESGENIS, A ;
GUINDO, J ;
VINOLAS, X ;
TOMAS, L ;
ELOSUA, R ;
DURAN, I ;
DELUNA, AB .
AMERICAN JOURNAL OF CARDIOLOGY, 1995, 76 (13) :D54-D59
[6]
Effect of nasal continuous positive airway pressure treatment on blood pressure in patients with obstructive sleep apnea [J].
Becker, HF ;
Jerrentrup, A ;
Ploch, T ;
Grote, L ;
Penzel, T ;
Sullivan, CE ;
Peter, JH .
CIRCULATION, 2003, 107 (01) :68-73
[7]
VALUE OF ECHOCARDIOGRAPHIC MEASUREMENT OF LEFT-VENTRICULAR MASS IN PREDICTING CARDIOVASCULAR MORBID EVENTS IN HYPERTENSIVE MEN [J].
CASALE, PN ;
DEVEREUX, RB ;
MILNER, M ;
ZULLO, G ;
HARSHFIELD, GA ;
PICKERING, TG ;
LARAGH, JH .
ANNALS OF INTERNAL MEDICINE, 1986, 105 (02) :173-178
[8]
Cardiac hypertrophy as a result of long-term thyroxine therapy and thyrotoxicosis [J].
Ching, GW ;
Franklyn, JA ;
Stallard, TJ ;
Daykin, J ;
Sheppard, MC ;
Gammage, MD .
HEART, 1996, 75 (04) :363-368
[9]
Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial [J].
Dargie, HJ ;
Colucci, Y ;
Ford, I ;
Sendon, JLL ;
Remme, W ;
Sharpe, N ;
Blank, A ;
Holcslaw, TL .
LANCET, 2001, 357 (9266) :1385-1390
[10]
Prognostic significance of left ventricular mass change during treatment of hypertension [J].
Devereux, RB ;
Wachtell, K ;
Gerdts, E ;
Boman, K ;
Nieminen, MS ;
Papademetriou, V ;
Rokkedal, J ;
Harris, K ;
Aurup, P ;
Dahlöf, B .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (19) :2350-2356